NCT05531214Completed
Creating A Cardiorenal Multidisciplinary Team for Management HF and CKD Patients
A Comparative Effectiveness Study to Assess the Impact of a Multidisciplinary Cardiorenal Care Team to Assist Primary Care Clinicians in Managing Patients With Heart Failure and Chronic Kidney Disease vs Usual Care.
Source: ClinicalTrials.gov · Last updated 26 Aug 2024
Brief summary (registry, in English)
Several drugs have been labeled as guideline-directed-medical therapies (GDMT) to improve overall health outcomes and slow the progression of disease in patients with heart failure (HF). Although scientific trials have deemed these drugs to be successful, many HF patients have been unable to either get started on the appropriate drug regimens or be optimized on the doses required to show substantial benefit, particularly in those who also suffer from chronic kidney disease (CKD). This is largely due to the current health care delivery model that requires a primary care clinician or general internist to refer patients to heart failure specialists and nephrologists. The specialty care itself then requires even more coordination resulting in patients getting lost to follow-up, physicians losing track of recommendations from different clinics, and too many separate electronic medical documentations to consolidate prior to deciding on what medication is appropriate at one thirty-minute outpatient visit. This study plans to create a new, virtual cardio-renal multidisciplinary team including a heart failure specialist and nephrologist to ease the coordination of care and consequently show a better implementation of GDMT in patients with HF and CKD when comparing those rates to the traditional referral-based way that these medications get prescribed.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 96 (actual)
- First submitted
- 10 Jun 2022
- Start date
- 1 Jun 2022
- Primary completion date
- 30 Jan 2023
- Lead sponsor
- George Washington University
- Diseases
- Chronic kidney disease, Heart failure
- NCT number
- NCT05531214
What you commit to
- Study type: Interventional
- Participants enrolled: 96
- From 1 Jun 2022 to the primary completion date, 30 Jan 2023
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Patients with a heart or kidney transplant
Age
- Patients \< 18 years of age
Other
- Patients on dialysis at the time of enrollment
- Pregnant
- Non-English speaking
- Patients that are unable to understand the process of the study and consent
Who the study is looking for
- 18 years of age or older
- History of HF with reduced ejection fraction (HFrEF) or ejection fraction (EF) \<50% and chronic kidney disease (CKD) with estimated glomerular filtration rate (eGFR) \< 60cc/min/1.73m2
Age in the registry: 18 years to - · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| George Washington University- Medical Faculty Associates Coordinator of this site? Confirm its status | Washington D.C. | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.